Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LXM-6
- Development stage
- Preclinical
- Lead developer
- Laxxon Medical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LXM-6 is a preclinical-stage small molecule therapeutic being developed by Laxxon Medical for the treatment of renal cell carcinoma. The drug is a 505(b)(2) reformulation of an existing, previously approved active pharmaceutical ingredient, utilizing Laxxon's proprietary SPID® (Screen Printed Innovative Drug) technology. This 3D screen-printing platform allows for the creation of complex oral dosage forms with precise, multi-phasic release profiles and improved bioavailability. By optimizing the delivery of established oncology treatments, LXM-6 aims to enhance efficacy and reduce side effects compared to conventional formulations.
Beyond the preview
Go deeper on LXM-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LXM-6.